New targets for heart-failure therapy: endothelin, inflammatory cytokines, and oxidative stress

[1]  OLAND,et al.  TREATMENT OF SEPTIC SHOCK WITH THE TUMOR NECROSIS FACTOR RECEPTOR : Fc FUSION PROTEIN C , 2000 .

[2]  A. Omran,et al.  Increased oxidative stress in patients with congestive heart failure. , 1998, Journal of the American College of Cardiology.

[3]  D. Chatel,et al.  Elevated levels of 8-iso-prostaglandin F2alpha in pericardial fluid of patients with heart failure: a potential role for in vivo oxidant stress in ventricular dilatation and progression to heart failure. , 1998, Circulation.

[4]  R. Peshock,et al.  Cardiac failure in transgenic mice with myocardial expression of tumor necrosis factor-alpha. , 1998, Circulation.

[5]  F. Clubb,et al.  Pathophysiologically relevant concentrations of tumor necrosis factor-alpha promote progressive left ventricular dysfunction and remodeling in rats. , 1998, Circulation.

[6]  K. Sliwa,et al.  Randomised investigation of effects of pentoxifylline on left-ventricular performance in idiopathic dilated cardiomyopathy , 1998, The Lancet.

[7]  D. Wagner,et al.  Adenosine inhibits lipopolysaccharide-induced secretion of tumor necrosis factor-alpha in the failing human heart. , 1998, Circulation.

[8]  N. Takahashi,et al.  Nitric oxide, atrial natriuretic peptide, and cyclic GMP inhibit the growth-promoting effects of norepinephrine in cardiac myocytes and fibroblasts. , 1998, The Journal of clinical investigation.

[9]  M. Creager,et al.  Increased sensitivity to nitric oxide synthase inhibition in patients with heart failure: potentiation of beta-adrenergic inotropic responsiveness. , 1998, Circulation.

[10]  D. Levy,et al.  Antioxidant effect of carvedilol and metoprolol in congestive heart failure , 1998 .

[11]  J. Cleland,et al.  Pulmonary and systemic responses to exogenous endothelin-1 in patients with left ventricular dysfunction. , 1998, Journal of cardiovascular pharmacology.

[12]  W. Colucci.  Molecular and cellular mechanisms of myocardial failure. , 1997, The American journal of cardiology.

[13]  K. Weber,et al.  Extracellular matrix remodeling in heart failure: a role for de novo angiotensin II generation. , 1997, Circulation.

[14]  P. Galuppo,et al.  Chronic endothelin receptor blockade attenuates progressive ventricular dilation and improves cardiac function in rats with myocardial infarction: possible involvement of myocardial endothelin system in ventricular remodeling. , 1997, Circulation.

[15]  S. Targan,et al.  A Short-Term Study of Chimeric Monoclonal Antibody cA2 to Tumor Necrosis Factor α for Crohn's Disease , 1997 .

[16]  A. Koretsky,et al.  Dilated Cardiomyopathy in Transgenic Mice With Cardiac-Specific Overexpression of Tumor Necrosis Factor-α , 1997 .

[17]  F. Lallemand,et al.  Role of endogenous endothelin in chronic heart failure: effect of long-term treatment with an endothelin antagonist on survival, hemodynamics, and cardiac remodeling. , 1997, Circulation.

[18]  E. Tindall,et al.  Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. , 1997, The New England journal of medicine.

[19]  R. Dixon,et al.  Discovery of TBC11251, a potent, long acting, orally active endothelin receptor-A selective antagonist. , 1997, Journal of Medicinal Chemistry.

[20]  M. Oz,et al.  Bridge experience with long-term implantable left ventricular assist devices. Are they an alternative to transplantation? , 1997, Circulation.

[21]  Bertram Pitt,et al.  Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE) , 1997, The Lancet.

[22]  B. Lopez,et al.  Peroxynitrite, the product of nitric oxide and superoxide, causes myocardial injury in the isolated perfused rat heart. , 1997, Coronary artery disease.

[23]  S. Goto,et al.  Characterization of cytokine and iNOS mRNA expression in situ during the course of experimental autoimmune myocarditis in rats. , 1997, Journal of molecular and cellular cardiology.

[24]  S. Targan,et al.  A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. , 1997, The New England journal of medicine.

[25]  D. Zechner,et al.  Tumor necrosis factor alpha-induced apoptosis in cardiac myocytes. Involvement of the sphingolipid signaling cascade in cardiac cell death. , 1996, The Journal of clinical investigation.

[26]  N. Goel,et al.  Oxy free radical system in heart failure and therapeutic role of oral vitamin E. , 1996, International journal of cardiology.

[27]  B. Pitt,et al.  IL-1 beta stimulates superoxide and delayed peroxynitrite production by pulmonary vascular smooth muscle cells. , 1996, The American journal of physiology.

[28]  Y. Sugishita,et al.  Inhibition of myocardial endothelin pathway improves long-term survival in heart failure , 1996, Nature.

[29]  D. Stewart,et al.  Human pulmonary circulation is an important site for both clearance and production of endothelin-1. , 1996, Circulation.

[30]  M. Matzuk,et al.  Neurodegeneration, myocardial injury, and perinatal death in mitochondrial superoxide dismutase-deficient mice. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[31]  J. Goldhaber.  Free radicals enhance Na+/Ca2+ exchange in ventricular myocytes. , 1996, The American journal of physiology.

[32]  D. Lalloo,et al.  Prevention of Jarisch-Herxheimer reactions by treatment with antibodies against tumor necrosis factor alpha. , 1996, The New England journal of medicine.

[33]  P. Singal,et al.  Role of oxidative stress in transition of hypertrophy to heart failure. , 1996, Journal of the American College of Cardiology.

[34]  S. Opal,et al.  Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group. , 1996, The New England journal of medicine.

[35]  M. Yacoub,et al.  Tumour necrosis factor and inducible nitric oxide synthase in dilated cardiomyopathy , 1996, The Lancet.

[36]  H. Oral,et al.  Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: a report from the Studies of Left Ventricular Dysfunction (SOLVD). , 1996, Journal of the American College of Cardiology.

[37]  P. Tsao,et al.  Expression of inducible nitric oxide synthase in human heart failure. , 1996, Circulation.

[38]  W. Colucci.  Myocardial endothelin. Does it play a role in myocardial failure? , 1996, Circulation.

[39]  Y. Sugishita,et al.  Endogenous endothelin-1 participates in the maintenance of cardiac function in rats with congestive heart failure. Marked increase in endothelin-1 production in the failing heart. , 1996, Circulation.

[40]  D. Mann,et al.  Tumor Necrosis Factor-α and Tumor Necrosis Factor Receptors in the Failing Human Heart , 1996 .

[41]  S. García-Castiñeiras,et al.  Increased malondialdehyde in peripheral blood of patients with congestive heart failure. , 1996, American heart journal.

[42]  P. Singal,et al.  Antioxidant and oxidative stress changes during heart failure subsequent to myocardial infarction in rats. , 1996, The American journal of pathology.

[43]  E. Sonnenblick,et al.  Stretch-induced programmed myocyte cell death. , 1995, The Journal of clinical investigation.

[44]  P. Hunziker,et al.  Evidence for endothelin-1-mediated vasoconstriction in severe chronic heart failure , 1995, The Lancet.

[45]  J. Hare,et al.  Role of nitric oxide in the regulation of myocardial function. , 1995, Progress in cardiovascular diseases.

[46]  N. Takahashi,et al.  Interleukin-1 beta modulates the growth and phenotype of neonatal rat cardiac myocytes. , 1995, The Journal of clinical investigation.

[47]  H. Krum,et al.  Role of endothelin in the exercise intolerance of chronic heart failure. , 1995, The American journal of cardiology.

[48]  W. Maksymowych,et al.  An open study of pentoxifylline in the treatment of severe refractory rheumatoid arthritis. , 1995, The Journal of rheumatology.

[49]  K. Swedberg,et al.  Coenzyme Q10 as an adjunctive in the treatment of chronic congestive heart failure. The Q10 Study Group. , 1995, Journal of cardiac failure.

[50]  P. Cannon,et al.  The lethal effects of cytokine-induced nitric oxide on cardiac myocytes are blocked by nitric oxide synthase antagonism or transforming growth factor beta. , 1995, The Journal of clinical investigation.

[51]  J. Vilček,et al.  Interferon-beta induces metalloproteinase mRNA expression in human fibroblasts. Role of activator protein-1. , 1994, The Journal of biological chemistry.

[52]  M. Yanagisawa,et al.  ECE-1: A membrane-bound metalloprotease that catalyzes the proteolytic activation of big endothelin-1 , 1994, Cell.

[53]  P. Singal,et al.  Antioxidant changes in hypertrophied and failing guinea pig hearts. , 1994, The American journal of physiology.

[54]  W. Edwards,et al.  Endothelin in human congestive heart failure. , 1994, Circulation.

[55]  J. McMurray,et al.  Evidence of oxidative stress in chronic heart failure in humans. , 1993, European heart journal.

[56]  F. Appelbaum,et al.  A randomized controlled trial of pentoxifylline for the prevention of regimen-related toxicities in patients undergoing allogeneic marrow transplantation , 1993 .

[57]  M. Arakawa,et al.  Comparative free radical scavenging action of angiotensin-converting enzyme inhibitors with and without the sulfhydryl radical. , 1993, Pharmacology.

[58]  J. Parrillo.  Pathogenetic mechanisms of septic shock. , 1993, The New England journal of medicine.

[59]  S. Moncada,et al.  Nitric oxide synthase activities in human myocardium , 1993, The Lancet.

[60]  J. Ferrara,et al.  Cytokine dysregulation and acute graft-versus-host disease. , 1992, Blood.

[61]  H. Blömer,et al.  Ubiquinone (coenzyme Q10) in the long-term treatment of idiopathic dilated cardiomyopathy. , 1992, European heart journal.

[62]  Hung‐Yuan Cheng,et al.  Carvedilol, a new vasodilator and beta adrenoceptor antagonist, is an antioxidant and free radical scavenger. , 1992, The Journal of pharmacology and experimental therapeutics.

[63]  P. Binkley,et al.  Plasma Endothelin Correlates With the Extent of Pulmonary Hypertension in Patients With Chronic Congestive Heart Failure , 1992, Circulation.

[64]  K. Chien,et al.  Endothelin induction of inositol phospholipid hydrolysis, sarcomere assembly, and cardiac gene expression in ventricular myocytes. A paracrine mechanism for myocardial cell hypertrophy. , 1990, The Journal of biological chemistry.

[65]  H. Fillit,et al.  Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. , 1990, The New England journal of medicine.

[66]  J. McMurray,et al.  Evidence for enhanced free radical activity in chronic congestive heart failure secondary to coronary artery disease. , 1990, The American journal of cardiology.

[67]  K. Folkers,et al.  Long-term efficacy and safety of coenzyme Q10 therapy for idiopathic dilated cardiomyopathy. , 1990, The American journal of cardiology.

[68]  P. Zabel,et al.  OXPENTIFYLLINE IN ENDOTOXAEMIA , 1989, The Lancet.

[69]  R. Strieter,et al.  Cellular and molecular regulation of tumor necrosis factor-alpha production by pentoxofylline , 1988 .

[70]  K. Folkers,et al.  Response of patients in classes III and IV of cardiomyopathy to therapy in a blind and crossover trial with coenzyme Q10. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[71]  J. McCord,et al.  Oxygen-derived free radicals in postischemic tissue injury. , 1985, The New England journal of medicine.